MAPT and Cognitive impairment: Alzheimer’s disease (AD) involves the progressive accumulation of amyloid-beta (Aβ) peptide and phosphorylated tau proteins, which are pivotal in the cognitive decline observed in AD and its clinical precursor stages, including mild cognitive impairment (MCI) (1).